Noopept (GVS-111)
Cognitive · Peptide-like
Tier C+
Bottom line
Read Off Label grades Noopept (GVS-111) as C+ (5.7/10) based on weak evidence, variable benefit magnitude, and a low-risk safety profile.
Developed at Zakusov Institute.
Typical use: 10-30 mg PO or sublingual daily — Rx in Russia; research chem elsewhere.
What this is
Developed at Zakusov Institute. ~1000x more potent than piracetam by weight. Common in nootropic stacks. Sublingual absorption well-reported. Anxiolytic effect distinguishes from other racetam-likes.
Mechanism
Proline-containing dipeptide structurally similar to piracetam; increases BDNF and NGF; cycloprolylglycine metabolite with anxiolytic activity
Dose & route
10-30 mg PO or sublingual daily
Citations
- https://pubmed.ncbi.nlm.nih.gov/11915081/
- https://pubmed.ncbi.nlm.nih.gov/19240132/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6121265/
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does Noopept (GVS-111) work?
- Read Off Label rates the evidence for Noopept (GVS-111) as Weak and the benefit magnitude as variable, producing an overall grade of C+ (5.7/10). Developed at Zakusov Institute.
- Is Noopept (GVS-111) safe?
- Noopept (GVS-111) has a low risk profile in published human data. Legal status: Rx in Russia; research chem elsewhere. This is not medical advice — see the disclaimer.
- What is the typical dose for Noopept (GVS-111)?
- 10-30 mg PO or sublingual daily
- How does Noopept (GVS-111) work?
- Proline-containing dipeptide structurally similar to piracetam; increases BDNF and NGF; cycloprolylglycine metabolite with anxiolytic activity
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.